POS0373 WHO ARE IN AND WHO ARE NOT? CHARACTERISTICS OF PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES ACCEPTING AN ONLINE SYSTEM FOR REMOTELY ENTERING PATIENT REPORTED OUTCOMES. EXPERIENCE FROM THE DANISH DANBIO REGISTRY

Background Digital solutions for online monitoring of chronic diseases are increasingly implemented in health care, but not all patients might have access, skills, or interest using them. Fueled by the COVID-19 pandemic and urgent need remote consultations, an website to enter patient-reported outcomes (PROs) from home (DANBIO-from-home, https://danbio.dk ) was on May 15 th 2020 with inflammatory rheumatic (IRD) followed Danish nationwide DANBIO registry. Objectives To explore use DANBIO-from-home during first 1½ year after launching, focus a) characteristics who did versus access webpage, b) impact patient age time entry. Methods allows PROs be entered remotely computer, tablet, smartphone secure log-on. All were informed about this option invitations sent through eBoks, a national infrastructure electronic communication, available 80-90% citizens. Patients encouraged before planned rheumatology when participating voluntary questionnaire survey ‘You your disease times corona-virus’ (on three occasions: 2020, Nov June 2021) (ref). Follow-up ended Dec 1 st 2021. Characteristics did/did follow-up explored multivariable logistic regression analyses adjusted clinical factors (gender/age-group/diagnosis/disease duration/use biologics/HAQ/PASS). Time entry PRO is presented as cumulative incidence curves group. Results Among 33,776 DANBIO, 68% used at least once (Table 1). system less frequently below 40 years above 80 old, more biologically treated had lower HAQ-score than it. Table 1. Data entry, solution N=33,776 YES, NO, 32% Gender, female 64 36 male 78 22 Age strata, yrs < 62 38 40-60 73 27 61-80 72 28 >80 39 61 Diagnosis RA 67 23 AxSpA 69 31 PsA 70 30 Biologic treatment, yes* PASS, yes 71 29 Age, yrs, median (IQR) (52-71) 65 (50-77) since diagnosis, 9 (5-16) 10 (5-17) HAQ, 0.5 (0.125-1.0) 0.625 (0.125-1.25) Row percentages unless otherwise shown * latest visit March AxSpA: Axial spondyloarthritis, HAQ: assessment questionnaire, PASS: acceptable symptom scale, PsA: psoriatic arthritis, RA: rheumatoid arthritis In analyses, associated were: gender (odds ratio, OR 1.2 (1.1;1.3)), group (1.8 (1.6;2.0)) (1.9 (1.7;2.19) (0.6 (0.5;0.7) <40 reference), biologic treatment (1.4 (1.3;1.5)), higher HAQ (1.3 (0.3;1.4)), scoring PASS ‘no’ (1.1 (1.02;1.2)) (all p <0.001), whereas duration diagnosis no impact. longest For age-groups, most pronounced increased surveys out. (Figure 1) Conclusion A web-based well-received launch. Patient-related substantial use. Lower elderly indicate lack technical skills facilities, low younger groups, which improved over time, likely driven other factors. Further if impacts outcomes. References [1]Glintborg et al, Rheumatology. 2021 Oct 9;60:SI3-SI12 Disclosure Interests Bente Glintborg Grant/research support from: AbbVie, BMS, Pfizer, Dorte Vendelbo Jensen: None declared, Lene Terslev Speakers bureau: Roche, Novartis, UCB, Janssen, Oliver Hendricks Mikkel Østergaard Abbvie, Boehringer-Ingelheim, Celgene, Eli-Lilly, Galapagos, Gilead, Hospira, Merck, Novo, Orion, Regeneron, Sandoz, Sanofi Simon Horskjær Rasmussen: Mogens Pfeiffer-Jensen: Thomas Adelsten: Ada Colic: Kamilla Danebod: Malene Kildemand: Anne Gitte Loft MSD, Heidi Lausten Munk: Jens Kristian Pedersen: René Østgård UCB., Christian Møller Sørensen: Niels Steen Krogh: Jette Nørgaard Agerbo: Connie Ziegler: Merete Lund Hetland Biogen, Celtrion, Eli Lilly Denmark A/S, Janssen Biologics B.V, Lundbeck Fonden, Samsung Biopis, Sandoz